Natera, Inc. Licensing and other revenues — Total revenues decreased by 36.0% to $2.78M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 54.7%, from $1.79M to $2.78M. Over 4 years (FY 2021 to FY 2025), Licensing and other revenues — Total revenues shows a downward trend with a -35.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests successful commercialization of proprietary technology and strong demand for the company's intellectual property, while a decrease may indicate expiring licenses or reduced partnership activity.
This metric represents the total revenue generated from licensing proprietary molecular and bioinformatics technology, i...
Comparable to 'Licensing Revenue' or 'Technology Access Fees' reported by other biotechnology and diagnostic firms that monetize their R&D through partnership models.
ntra_segment_licensing_and_other_revenues_total_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.79M | $7.47M | $12.14M | $4.13M | $3.62M | $10.81M | $4.36M | $3.96M | $3.15M | $3.09M | $3.85M | $3.07M | $1.99M | $3.63M | $3.15M | $1.79M | $2.17M | $1.99M | $4.34M | $2.78M |
| QoQ Change | — | +55.7% | +62.7% | -66.0% | -12.4% | +198.7% | -59.7% | -9.2% | -20.5% | -1.9% | +24.8% | -20.4% | -35.3% | +82.7% | -13.2% | -43.0% | +21.1% | -8.6% | +118.5% | -36.0% |
| YoY Change | — | — | — | — | -24.5% | +44.8% | -64.1% | -4.2% | -13.0% | -71.4% | -11.6% | -22.5% | -36.9% | +17.6% | -18.3% | -41.5% | +9.4% | -45.3% | +37.8% | +54.7% |